Litigation Details for Chugai Pharmaceutical Co., Ltd. v. Alexion Pharmaceuticals, Inc. (D. Del. 2018)
✉ Email this page to a colleague
Chugai Pharmaceutical Co., Ltd. v. Alexion Pharmaceuticals, Inc. (D. Del. 2018)
| Docket | ⤷ Sign Up | Date Filed | 2018-11-15 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:1 Patent Infringement | Assigned To | Maryellen Noreika |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 9,079,949 | ||
| Link to Docket | External link to docket | ||
Biologic Drugs cited in Chugai Pharmaceutical Co., Ltd. v. Alexion Pharmaceuticals, Inc.
The biologic drug covered by the patent cited in this case is ⤷ Sign Up .
Details for Chugai Pharmaceutical Co., Ltd. v. Alexion Pharmaceuticals, Inc. (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-11-15 | 1 | antibody in U.S. Patent No. 9,079,949 (“the ’949 patent”). 30. The ’949 patent is entitled “Anti-C5…pending patent applications and by U.S. Patent No. 9,890,377 (“the ’377 patent” or “the Patent-in-Suit…described in the ’377 patent began before 2010. The ’377 patent stems from a series of patent applications claiming… of the ’377 patent and/or the underlying patent applications that led to the ’377 patent. 38.… This is an action for patent infringement and declaratory judgment of patent infringement. Chugai brings | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
